Kiadis Pharma is a biotechnology company specializing in the development of innovative cell-based immunotherapies aimed at treating life-threatening diseases, particularly cancer. The company focuses on leveraging its proprietary off-the-shelf NK (natural killer) cell platform, which utilizes NK cells from a unique universal donor to create effective treatments. Kiadis serves patients undergoing hematopoietic stem cell transplants and those battling blood cancers and solid tumors. Operating in the biopharmaceutical market, Kiadis employs a business model centered around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through partnerships, licensing agreements, and sales of approved treatments. The company's core values emphasize patient-centricity, transparency, collaboration, urgency, and quality.

Keywords: immunotherapy, NK cells, cancer treatment, stem cell transplant, biotechnology, biopharmaceutical, cell-based therapy, universal donor, clinical trials, patient-centric.